Skip to main content
Erschienen in: Clinical Rheumatology 3/2009

01.03.2009 | Brief Report

Diagnosis delay in patients with ankylosing spondylitis: factors and outcomes—an Indian perspective

verfasst von: Rohit Aggarwal, Anand N. Malaviya

Erschienen in: Clinical Rheumatology | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

This study focuses on the causes and consequences of delay in diagnosis of ankylosing spondylitis (AS). Seventy consecutive patients presenting at a rheumatology clinic in India were studied. Mean (±S.D) delay in diagnosis was 6.9 (±5.2) years. The main cause of delay was incorrect diagnosis as non-specific back pain (19/54, 35.1%), degenerative disc disease (14/54, 25.9%), rheumatoid arthritis (11/54, 20.37%), and tuberculosis of spine (9/54, 16.6%) in that order, for which the patient received prolonged treatment. Absence of extra-articular manifestations and juvenile age also significantly correlated with diagnostic delay. Delay in diagnosis resulted in significantly worse disease activity index (BASDAI), functional index (BASFI), and damage index (BASMI). Most incorrect initial diagnoses were made by orthopedicians (75.9%), followed by general physician (50%), and rheumatologist (12%). Continuing medical education workshops with a focus on clinical diagnosis of inflammatory back pain may help in early diagnosis of AS.
Literatur
1.
Zurück zum Zitat Khan MA (2002) Ankylosing spondylitis: introductory comments on its diagnosis and treatment. Ann Rheum Dis 61(Suppl 3):iii3–iii7PubMed Khan MA (2002) Ankylosing spondylitis: introductory comments on its diagnosis and treatment. Ann Rheum Dis 61(Suppl 3):iii3–iii7PubMed
2.
Zurück zum Zitat Dincer U, Cakar E, Kiralp MZ, Dursun H (2008) Diagnosis delay in patients with ankylosing spondylitis: possible reasons and proposals for new diagnostic criteria. Clin Rheumatol 27(4):457–462PubMedCrossRef Dincer U, Cakar E, Kiralp MZ, Dursun H (2008) Diagnosis delay in patients with ankylosing spondylitis: possible reasons and proposals for new diagnostic criteria. Clin Rheumatol 27(4):457–462PubMedCrossRef
3.
Zurück zum Zitat Feldtkeller E, Erlendsson J (2008) Definition of disease duration in ankylosing spondylitis. Rheumatol Int 28(7):693–696PubMedCrossRef Feldtkeller E, Erlendsson J (2008) Definition of disease duration in ankylosing spondylitis. Rheumatol Int 28(7):693–696PubMedCrossRef
4.
Zurück zum Zitat Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J (2003) Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 23(2):61–66PubMed Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J (2003) Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 23(2):61–66PubMed
5.
Zurück zum Zitat Van Den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H et al (2002) Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 46(3):755–765CrossRef Van Den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H et al (2002) Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 46(3):755–765CrossRef
6.
Zurück zum Zitat Gorman JD, Sack KE, Davis JC Jr (2002) Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 346(18):1349–1356PubMedCrossRef Gorman JD, Sack KE, Davis JC Jr (2002) Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 346(18):1349–1356PubMedCrossRef
7.
Zurück zum Zitat Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L et al (2003) Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48(6):1667–1675PubMedCrossRef Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L et al (2003) Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48(6):1667–1675PubMedCrossRef
8.
Zurück zum Zitat Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J (2004) Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 63(6):665–670PubMedCrossRef Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J (2004) Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 63(6):665–670PubMedCrossRef
10.
Zurück zum Zitat Moll JM, Wright V (1973) New York clinical criteria for ankylosing spondylitis. A statistical evaluation. Ann Rheum Dis 32(4):354–363PubMedCrossRef Moll JM, Wright V (1973) New York clinical criteria for ankylosing spondylitis. A statistical evaluation. Ann Rheum Dis 32(4):354–363PubMedCrossRef
11.
Zurück zum Zitat Oostveen J, Prevo R, den Boer J, van de Laar M (1999) Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography. A prospective, longitudinal study. J Rheumatol 26(9):1953–1958PubMed Oostveen J, Prevo R, den Boer J, van de Laar M (1999) Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography. A prospective, longitudinal study. J Rheumatol 26(9):1953–1958PubMed
12.
Zurück zum Zitat Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J et al (2003) Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 48(4):1126–1136PubMedCrossRef Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J et al (2003) Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 48(4):1126–1136PubMedCrossRef
13.
Zurück zum Zitat van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361–368PubMedCrossRef van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361–368PubMedCrossRef
14.
Zurück zum Zitat van der Heijde D, van der Linden S, Bellamy N, Calin A, Dougados M, Khan MA (1999) Which domains should be included in a core set for endpoints in ankylosing spondylitis? Introduction to the ankylosing spondylitis module of OMERACT IV. J Rheumatol 26(4):945–947PubMed van der Heijde D, van der Linden S, Bellamy N, Calin A, Dougados M, Khan MA (1999) Which domains should be included in a core set for endpoints in ankylosing spondylitis? Introduction to the ankylosing spondylitis module of OMERACT IV. J Rheumatol 26(4):945–947PubMed
15.
Zurück zum Zitat Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286–2291PubMed Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286–2291PubMed
16.
Zurück zum Zitat Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21(12):2281–2285PubMed Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21(12):2281–2285PubMed
17.
Zurück zum Zitat Jones SD, Porter J, Garrett SL, Kennedy LG, Whitelock H, Calin A (1995) A new scoring system for the Bath Ankylosing Spondylitis Metrology Index (BASMI). J Rheumatol 22(8):1609PubMed Jones SD, Porter J, Garrett SL, Kennedy LG, Whitelock H, Calin A (1995) A new scoring system for the Bath Ankylosing Spondylitis Metrology Index (BASMI). J Rheumatol 22(8):1609PubMed
18.
Zurück zum Zitat Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359(9313):1187–1193PubMedCrossRef Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359(9313):1187–1193PubMedCrossRef
19.
Zurück zum Zitat Baraliakos X, Listing J, von der Recke A et al (2008) The long-term natural course of radiographic progression in ankylosing spondylitis—evaluation of a large AS cohort Scand J Rheumatol 37(123s):33. [Abstract from the 32nd Scandinavian Congress of Rheumatology Jan 30–Feb 3, 2008, held at Levi, Lapland, Finland] Baraliakos X, Listing J, von der Recke A et al (2008) The long-term natural course of radiographic progression in ankylosing spondylitis—evaluation of a large AS cohort Scand J Rheumatol 37(123s):33. [Abstract from the 32nd Scandinavian Congress of Rheumatology Jan 30–Feb 3, 2008, held at Levi, Lapland, Finland]
20.
Zurück zum Zitat Calin A, Elswood J, Rigg S, Skevington SM (1988) Ankylosing spondylitis—an analytical review of 1500 patients: the changing pattern of disease. J Rheumatol 15(8):1234–1238PubMed Calin A, Elswood J, Rigg S, Skevington SM (1988) Ankylosing spondylitis—an analytical review of 1500 patients: the changing pattern of disease. J Rheumatol 15(8):1234–1238PubMed
21.
Zurück zum Zitat Malaviya AN (2003) The Feng Pao Hsii lecture: rheumatology in the Asia-Pacific region—unmet needs and challenges. APLAR J Rheumatol 6(1):68–76CrossRef Malaviya AN (2003) The Feng Pao Hsii lecture: rheumatology in the Asia-Pacific region—unmet needs and challenges. APLAR J Rheumatol 6(1):68–76CrossRef
22.
Zurück zum Zitat Rudwaleit M, Metter A, Listing J, Sieper J, Braun J (2006) Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 54(2):569–578PubMedCrossRef Rudwaleit M, Metter A, Listing J, Sieper J, Braun J (2006) Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 54(2):569–578PubMedCrossRef
Metadaten
Titel
Diagnosis delay in patients with ankylosing spondylitis: factors and outcomes—an Indian perspective
verfasst von
Rohit Aggarwal
Anand N. Malaviya
Publikationsdatum
01.03.2009
Verlag
Springer-Verlag
Erschienen in
Clinical Rheumatology / Ausgabe 3/2009
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-008-1049-z

Weitere Artikel der Ausgabe 3/2009

Clinical Rheumatology 3/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.